
Opinion|Videos|October 10, 2024
KEYNOTE-811: Latest Updates From ESMO 2024
Panelists discuss how KEYNOTE-811's study design and key findings presented at the European Society for Medical Oncology (ESMO) Congress 2024 demonstrate the potential impact of pembrolizumab plus trastuzumab and chemotherapy in HER2-positive gastric cancer treatment.





































